

Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021

<https://marketpublishers.com/r/A74366448BBEEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A74366448BBEEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Atypical Teratoid Rhabdoid Tumors (ATRT) Understanding

Atypical Teratoid Rhabdoid Tumors (ATRT): Overview

Atypical teratoid rhabdoid tumors (ATRT) are very rare, aggressive tumors of the central nervous system, occurring mostly in the cerebellum or the brain stem and are more commonly diagnosed in young children. The signs and symptoms of atypical teratoid rhabdoid tumor varies with patient to patient and depend on the child's age as well as tumor location. A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Treatment

of ATRT mainly includes surgery, chemotherapy or radiation therapy. Combinatorial treatment of surgical resection, chemotherapy, and radiation therapy is widely used. Multiple clinical trials testing molecularly targeted therapies are underway.

'Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape is provided which includes the disease overview and Atypical Teratoid Rhabdoid Tumors (ATRT) treatment guidelines. The assessment part of the report embraces, in depth Atypical Teratoid Rhabdoid Tumors (ATRT) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atypical Teratoid Rhabdoid Tumors (ATRT) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Teratoid Rhabdoid Tumors (ATRT) R&D. The therapies under development are focused on novel approaches to treat/improve Atypical Teratoid Rhabdoid Tumors (ATRT).

Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs Chapters

This segment of the Atypical Teratoid Rhabdoid Tumors (ATRT) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atypical Teratoid Rhabdoid Tumors (ATRT) Emerging Drugs

Tazemetostat: Epizyme

Tazemetostat is an orally administered, first-in-class small molecule EZH2 inhibitor, for

the treatment of multiple types of hematological malignancies and genetically defined solid tumors. In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors. Epizyme is developing tazemetostat for Atypical Teratoid Rhabdoid Tumors and is currently in phase II stage of development.

ONC206: Chimerix

ONC206 is a DRD2 antagonist and ClpP agonist with nanomolar potency that demonstrates enhanced non-competitive DRD2 antagonism relative to ONC201, and disruption of DRD2 homodimers. ONC206 exhibits a distinct gene expression profile as well as single agent and combinatorial efficacy with ONC201 in cells with acquired resistance to ONC201. The drug is in Phase I clinical studies for the treatment of recurrent and rare primary central nervous system neoplasms.

Further product details are provided in the report

Atypical Teratoid Rhabdoid Tumors (ATRT): Therapeutic Assessment

This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors (ATRT) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atypical Teratoid Rhabdoid Tumors (ATRT)

There are approx. 10+ key companies which are developing the therapies for Atypical Teratoid Rhabdoid Tumors (ATRT). The companies which have their Atypical Teratoid Rhabdoid Tumors (ATRT) drug candidates in the most advanced stage, i.e. Phase II include, Epizyme.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atypical Teratoid Rhabdoid Tumors (ATRT): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors (ATRT) drugs.

Atypical Teratoid Rhabdoid Tumors (ATRT) Report Insights

Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Atypical Teratoid Rhabdoid Tumors (ATRT) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Atypical Teratoid Rhabdoid Tumors (ATRT) drugs?

How many Atypical Teratoid Rhabdoid Tumors (ATRT) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atypical Teratoid Rhabdoid Tumors (ATRT)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atypical Teratoid Rhabdoid Tumors (ATRT) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Atypical Teratoid Rhabdoid Tumors (ATRT) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Takeda Oncology

Chimerix

Epizyme

Pfizer

Vyriad

DNATRIX

Lantern Pharma

Key Products

Alisertib

ONC206

Tazemetostat

Palbociclib

MV-NIS

DNX-2401

LP-184

Contents

Introduction

Executive Summary

Atypical Teratoid Rhabdoid Tumors (ATRT): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Atypical Teratoid Rhabdoid Tumors (ATRT) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Atypical Teratoid Rhabdoid Tumors (ATRT) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Atypical Teratoid Rhabdoid Tumors (ATRT) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tazemetostat: Epizyme

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ONC206: Chimerix

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical/Discovery Stage Products

Comparative Analysis

DNX-2401: DNAtrix

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies

Atypical Teratoid Rhabdoid Tumors (ATRT) Key Products

Atypical Teratoid Rhabdoid Tumors (ATRT)- Unmet Needs

Atypical Teratoid Rhabdoid Tumors (ATRT)- Market Drivers and Barriers

Atypical Teratoid Rhabdoid Tumors (ATRT)- Future Perspectives and Conclusion

Atypical Teratoid Rhabdoid Tumors (ATRT) Analyst Views

Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Atypical Teratoid Rhabdoid Tumors (ATRT)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Atypical Teratoid Rhabdoid Tumors (ATRT) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A74366448BBEEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A74366448BBEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970